Tumor Necrosis Factor Receptor Superfamily, Member 9
"Tumor Necrosis Factor Receptor Superfamily, Member 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053261
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.220
|
| Concept/Terms |
Tumor Necrosis Factor Receptor Superfamily, Member 9- Tumor Necrosis Factor Receptor Superfamily, Member 9
- 4-1BB Receptor
- 4 1BB Receptor
- Receptor, 4-1BB
- CD137 Antigen
- Antigen, CD137
- CD137 Antigens
- Antigens, CD137
- TNFRSF9 Receptor
- Receptor, TNFRSF9
- 4-1BB Receptors
- 4 1BB Receptors
- Receptors, 4-1BB
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Receptor Superfamily, Member 9".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Receptor Superfamily, Member 9".
This graph shows the total number of publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 9" by people in this website by year, and whether "Tumor Necrosis Factor Receptor Superfamily, Member 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 9" by people in Profiles.
-
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies. Clin Cancer Res. 2025 Jan 17; 31(2):288-298.
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
-
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024; 13(1):2388304.
-
Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Mol Ther. 2024 Oct 02; 32(10):3504-3521.
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
-
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 02; 10(2).
-
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer. 2021 07; 9(7).
-
Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. J Immunother Cancer. 2021 04; 9(4).
-
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020 03 12; 5(5).
-
CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood. 2019 10 31; 134(18):1510-1516.